All In Biotech

Investigational drug · Phase 2

CHF10067

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Idiopathic Pulmonary Fibrosis.

Phase 2

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

2

Any phase or sponsor naming "CHF10067"

First trial start

2026

Jul 8, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "CHF10067", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Idiopathic Pulmonary Fibrosis

Approved drugs for the same conditions: Idiopathic pulmonary fibrosis · Respiratory

Largest trials

Live from ClinicalTrials.gov: studies naming "CHF10067" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Idiopathic Pulmonary Fibrosis

  • HSK44459Phase 39 trials

    Haisco Pharmaceutical Group Co., Ltd. · Psoriasis, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis

  • Inhaled TreprostinilLIQ861 Inhaled Treprostinil, Inhaled prostacyclinPhase 35 trials

    United Therapeutics · Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis

  • BMS-986278AdmilparantPhase 33 trials

    Bristol Myers Squibb · Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis

  • HEC585Phase 33 trials

    Sunshine Lake Pharma Co., Ltd. · Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF), Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)

  • BI 1015550Phase 32 trials

    Boehringer Ingelheim · Lung Diseases, Interstitial, Idiopathic Pulmonary Fibrosis

  • DeupirfenidonePhase 32 trials

    PureTech · Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis

  • INS018_055Phase 32 trials

    InSilico Medicine Hong Kong Limited · Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis

  • REGEND001Phase 32 trials

    Regend Therapeutics · COPD (Chronic Obstructive Pulmonary Disease), Idiopathic Pulmonary Fibrosis

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.